Background It has been suggested that withdrawal of inhaled corticosteroids (ICS) in COPD
patients on maintenance treatment results in deterioration of symptoms, lung function and …

Background Chronic obstructive pulmonary disease (COPD) is a chronic and progressive
disease that affects an estimated 10% of the world's population over the age of 40 years …

Introduction Combined inhaled long-acting beta-agonists and corticosteroids (LABA+ ICS)
are costly. They are recommended in severe or very severe chronic obstructive pulmonary …

Purpose The literature was reviewed to determine whether data support current treatment
guideline recommendations regarding the use of systemic corticosteroids in the treatment of …

Background Long‐acting beta 2‐agonists and inhaled corticosteroids can be used as
maintenance therapy by patients with moderate to severe chronic obstructive pulmonary …

Inhaled corticosteroids (ICS) are the mainstay of treatment for asthma, but their role in
chronic obstructive pulmonary disease (COPD) is debated. Recent randomised controlled …

Long-acting bronchodilators in combination with inhaled corticosteroids (ICS) are
recommended to decrease the risk of recurrent exacerbations in patients with Global …

Objective To determine whether systemic corticosteroids are of benefit to patients with acute
exacerbations of chronic obstructive pulmonary disease (COPD). Methods An English …

Despite rapid advances in our understanding of its pathophysiology, chronic obstructive
pulmonary disease (COPD) remains incurable. Although bronchodilators and theophyllines …

Introduction: Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease. To estimate the association between …